



Corporate Press Release

23rd June 2011

First MOVIPREP[®] launch in Central and Eastern Europe

Norgine and PharmaSwiss are pleased to announce the launch in Slovenia of MOVIPREP, a bowel cleansing preparation. This is the first launch by PharmaSwiss of MOVIPREP in Central and Eastern Europe, with other launches scheduled over the coming months.

Commenting on the launch Valeant CEO Europe Mariusz Gajowniczek said: "We are very happy to be launching this excellent product in Central and Eastern Europe. Valeant's historically strong presence in Northern Europe, now combined with the strength of PharmaSwiss in Southern Europe, will provide a solid foundation for a successful launch for not only MOVIPREP, but for future products through our partnership with Norgine"

Commenting on the launch, Norgine's CEO Peter Stein said: "We are delighted that our partners PharmaSwiss have launched MOVIPREP in Slovenia. This is the first of many MOVIPREP launches planned for Central and Eastern Europe by PharmaSwiss. Their extensive sales and distribution network, coupled with their commitment to improve the detection of bowel disease, will bring significant benefits to both patients and healthcare professionals in the region"

MOVIPREP is marketed by Norgine in Europe, by Salix Pharmaceuticals in the USA, by Medical Futures in Canada and is under development by Ajinomoto in Japan.

ENDS

About Norgine

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine's net product sales were €258 million. The Company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®]

for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com

About PharmaSwiss

PharmaSwiss SA, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), is a multinational specialty pharmaceutical company based in Zug, Switzerland. The company represents major research-based multinationals such as Amgen, Astellas, BMS, Ferring, Ipsen, Lilly, Norgine, Pfizer and Reckitt-Benckiser and also in-licenses and markets its own brands. More information about PharmaSwiss can be found at www.pharmaswiss.com

PharmaSwiss Contact

John Connolly
Regional General Manager
+42 0 234 719600
john.connolly@pharmaswiss.com